Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
- 1 June 1998
- journal article
- research article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 10 (3) , 330-336
- https://doi.org/10.1016/s0952-7915(98)80172-6
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- TOR2 is required for organization of the actin cytoskeleton in yeastProceedings of the National Academy of Sciences, 1996
- IMMUNOPHARMACOLOGY OF RAPAMYCINAnnual Review of Immunology, 1996
- When is a lipid kinase not a lipid kinase? When it is a protein kinaseCell, 1995
- Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian CellsJournal of Biological Chemistry, 1995
- RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.Proceedings of the National Academy of Sciences, 1994
- RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORsCell, 1994
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994
- Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.Molecular and Cellular Biology, 1993
- Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progressionCell, 1993
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991